These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 18410085

  • 21. Classification and regression trees--studies of HIV reverse transcriptase inhibitors.
    Daszykowski M, Walczak B, Xu QS, Daeyaert F, de Jonge MR, Heeres J, Koymans LM, Lewi PJ, Vinkers HM, Janssen PA, Massart DL.
    J Chem Inf Comput Sci; 2004; 44(2):716-26. PubMed ID: 15032554
    [Abstract] [Full Text] [Related]

  • 22. Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments.
    Brandt P, Geitmann M, Danielson UH.
    J Med Chem; 2011 Feb 10; 54(3):709-18. PubMed ID: 21207958
    [Abstract] [Full Text] [Related]

  • 23. Design of potential reverse transcriptase inhibitor containing Isatin nucleus using molecular modeling studies.
    Pawar V, Lokwani D, Bhandari S, Mitra D, Sabde S, Bothara K, Madgulkar A.
    Bioorg Med Chem; 2010 May 01; 18(9):3198-211. PubMed ID: 20381364
    [Abstract] [Full Text] [Related]

  • 24. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.
    Gussio R, Pattabiraman N, Zaharevitz DW, Kellogg GE, Topol IA, Rice WG, Schaeffer CA, Erickson JW, Burt SK.
    J Med Chem; 1996 Apr 12; 39(8):1645-50. PubMed ID: 8648604
    [Abstract] [Full Text] [Related]

  • 25. Flexible docking of pyridinone derivatives into the non-nucleoside inhibitor binding site of HIV-1 reverse transcriptase.
    Medina-Franco JL, Rodríguez-Morales S, Juárez-Gordiano C, Hernández-Campos A, Jiménez-Barbero J, Castillo R.
    Bioorg Med Chem; 2004 Dec 01; 12(23):6085-95. PubMed ID: 15519154
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S, Mavromoustakos T, Chronakis N, Papadopoulos MG.
    Bioorg Med Chem; 2008 Dec 01; 16(23):9957-74. PubMed ID: 18996019
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads.
    Vadivelan S, Deeksha TN, Arun S, Machiraju PK, Gundla R, Sinha BN, Jagarlapudi SA.
    Eur J Med Chem; 2011 Mar 01; 46(3):851-9. PubMed ID: 21272964
    [Abstract] [Full Text] [Related]

  • 32. Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model.
    Kolb P, Huang D, Dey F, Caflisch A.
    J Med Chem; 2008 Mar 13; 51(5):1179-88. PubMed ID: 18271520
    [Abstract] [Full Text] [Related]

  • 33. Comparison of ligand-based and structure-based 3D-QSAR approaches: a case study on (aryl-)bridged 2-aminobenzonitriles inhibiting HIV-1 reverse transcriptase.
    Sciabola S, Carosati E, Baroni M, Mannhold R.
    J Med Chem; 2005 Jun 02; 48(11):3756-67. PubMed ID: 15916427
    [Abstract] [Full Text] [Related]

  • 34. Drug resistant mechanism of diaryltriazine analog inhibitors of HIV-1 reverse transcriptase using molecular dynamics simulation and 3D-QSAR.
    Li Z, Zhang H, Li Y, Zhang J, Chen HF.
    Chem Biol Drug Des; 2011 Jan 02; 77(1):63-74. PubMed ID: 21134218
    [Abstract] [Full Text] [Related]

  • 35. Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.
    Singh P, Mhaka AM, Christensen SB, Gray JJ, Denmeade SR, Isaacs JT.
    J Med Chem; 2005 Apr 21; 48(8):3005-14. PubMed ID: 15828839
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Molecular dynamics simulations of 2-amino-6-arylsulphonylbenzonitriles analogues as HIV inhibitors: interaction modes and binding free energies.
    Hu R, Barbault F, Maurel F, Delamar M, Zhang R.
    Chem Biol Drug Des; 2010 Dec 21; 76(6):518-26. PubMed ID: 20942836
    [Abstract] [Full Text] [Related]

  • 38. Assessing molecular docking tools for relative biological activity prediction: a case study of triazole HIV-1 NNRTIs.
    Frączek T, Siwek A, Paneth P.
    J Chem Inf Model; 2013 Dec 23; 53(12):3326-42. PubMed ID: 24266618
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
    Mandal AS, Roy K.
    Eur J Med Chem; 2009 Apr 23; 44(4):1509-24. PubMed ID: 18760864
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.